A physIQ + OncoBay On-Demand Webinar

Strategies to Expand Access to Immuno-Oncology Trials and Treatments

Barriers to access for immuno-oncology therapies like CAR-T are threatening the promise of these lifesaving treatments. A small number of approved therapies that often face manufacturing challenges, the limited number of treatment centers, the high costs, and the post-treatment monitoring requirements make bringing this miracle to market in a widely accessible way a serious challenge. 
 
OncoBay Clinical, a CRO specializing in complex immuno-oncology programs, has recently partnered with physIQ to make immuno-oncology trials, and ultimately marketed therapies, more accessible for patients through a predict-to-prevent safety monitoring solution using continuous remote patient data.
 
The webinar includes an explanation of the physIQ/OncoBay “physiology-first” data model and a demonstration of how physIQ’s continuous remote patient monitoring technology provides predictive patients insights for OncoBay’s clinical trial sponsors. We also discuss how this improved immuno-oncology trial model can have positive results such as:

• Increasing the likelihood of IRB and regulatory approval
• Overcoming the geographical challenges of immuno-oncology trial participation
• Keeping patients safe both in and out of traditional clinical care settings
• Reducing the cost burden of immuno-oncology trials and therapy administration
• Increasing immuno-oncology treatment capacity without increasing treatment centers